First Wave BioPharma, Inc. Announces Private Placement
July 15, 2022 08:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., July 15, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
Inflammatory Bowel Disease Treatment Market Size [2022-2029]: $37.00 Billion by 2029 at CAGR of 5.7%
May 30, 2022 08:10 ET
|
Fortune Business Insights
Pune, India, May 30, 2022 (GLOBE NEWSWIRE) -- The global inflammatory bowel disease treatment market size was valued at USD 23.90 billion in 2021. The market is projected to grow from USD 25.18...
Metacrine Reports First-Quarter 2022 Results
May 12, 2022 16:05 ET
|
Metacrine, Inc.
SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases,...
First Wave BioPharma Forms Clinical Steering Committee Focused on Advancing Inflammatory Bowel Disease (IBD) Product Portfolio
April 27, 2022 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., April 27, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Global Inflammatory Bowel Disease (IBD) Drugs market is projected to grow at a CAGR of 3.77% by 2031: Visiongain Research Inc
April 19, 2022 11:00 ET
|
Visiongain Ltd
Visiongain has published a new report on Inflammatory Bowel Disease Drugs Market Report 2021-2031. Profiles of Inflammatory Bowel Disease Drugs and Forecasts by Drug Class (Biologics,...
Metacrine Reports Fourth-Quarter 2021 Results
March 30, 2022 16:05 ET
|
Metacrine, Inc.
SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal...
First Wave BioPharma to Participate in ”Fireside Chat” at the 34th Annual Roth Conference
March 08, 2022 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., March 08, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Announces Poster Presentation at the 2022 Digestive Disease Week (DDW) Conference
March 03, 2022 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., March 03, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma, Inc. Announces Closing of $9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
March 02, 2022 17:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., March 02, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (the “Company”), a clinical stage biopharmaceutical company specializing in the development of...
First Wave BioPharma Announces Appointment of Sarah Romano as Chief Financial Officer
March 01, 2022 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., March 01, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...